Dublin, July 03, 2018 (GLOBE NEWSWIRE) -- The "Intravenous (IV) Iron Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets.
This report analyzes the worldwide markets for Intravenous (IV) Iron Drugs in US$ Thousand. The report profiles 21 companies including many key and niche players such as:
- Allergan Plc. (Ireland)
- AMAG Pharmaceuticals, Inc. (USA)
- Daiichi Sankyo, Inc. (USA)
- Luitpold Pharmaceuticals, Inc. (USA)
- American Regent, Inc. (USA)
- Pharmacosmos A/S (Denmark)
- Sanofi US (USA)
- Vifor Pharma Ltd. (Switzerland)
- Vifor Fresenius Medical Care Renal Pharma (Switzerland)
Key Topics Covered
1. GLOBAL MARKET OVERVIEW Iron Deficiency Anemia (IDA) An Overview Intravenous (IV) Iron Drugs Market A Quick Primer US and Europe Dominate IV Iron Market Asia-Pacific The Fastest Growing Market Leading Intravenous Iron Drugs Globally Leading IV Iron Drugs Available in the Market Leading Intravenous Iron Drugs: In a Nutshell Ferinject/Injectafer The Leading Intravenous Iron Drug Globally Venofer® Looses Ground to Ferinject Feraheme Obtains Broader Label Approval Feraheme® Obtains FDA Filing Acceptance for Treating All Adult Patients Suffering from IDA Gluconate (Ferrlecit® and Nulecit) Dextran Global Market Leaders 2. GROWTH DRIVERS & MARKET TRENDS Expanding Pool of ESRD and CKD Patients The Major Growth Driver for Intravenous (IV) Iron Drugs ESRD Prevalence Statistics: An Opportunity Indicator Increase in Healthcare Spending Bodes Well for Intravenous Iron Drugs Market Dialysis Patients A Major Market for Intravenous Iron Supplements Ageing Population Drives Demand for IV Iron Drugs Shifting Preference from Oral Iron Drugs to Intravenous Iron Drugs Comparison of Ferrous Salts with IV Iron Therapy Other Chronic Diseases with IDA Offer Prospects for IV Iron Drugs Anemia in Heart Failure A Market with Huge Potential Chemotherapy Induced Anemia to Promote IV Iron Supplements Correction of IDA in Pregnancy Signals Opportunities Women’s Health A Key Growth Opportunity Perioperative and Postoperative Anemia A Niche Market Beckons Adverse Reactions of IV Iron Preparations Raise Concerns Dosing Limitations Plague IV Iron Market Select Therapeutic Areas and the Required Iron Doses 3. REGULATORY OVERVIEW Increasing Trend towards Bundled Reimbursements A Glimpse of Regulations in the US and Europe Comparison of Approved Indications and Safety Warnings for Select FDA Approved IV Iron Drugs Coverage of IV Iron and ESA in the Reimbursement Packages of Dialysis Services across Belgium, Germany, Netherlands, the UK, France, the US and Ontario, Canada 4. OVERVIEW OF INTRAVENOUS (IV) IRON DRUGS 5. RECENT INDUSTRY ACTIVITY AMAG to Expand Feraheme® Label Pharmacosmos and Laboratoire Aguettant to Commercialize Monover® in France Pharmacosmos and Pfizer to Commercialize Monover® in Brazil Rockwell Medical Announces Data Presentation on Triferic Intravenous (IV) Administration Nippon Shinyaku and Pharmacosmos to Develop and commercialize Monofer® in Japan Lupin Announces the Launch of Novel Injectable Iron Formulation in India Pharmacosmos and Pfizer to Commercialize Monofer® in Canada 6. FOCUS ON SELECT PLAYERS Allergan Plc. (Ireland) AMAG Pharmaceuticals, Inc. (USA) Daiichi Sankyo, Inc. (USA) Luitpold Pharmaceuticals, Inc. (USA) American Regent, Inc. (USA) Pharmacosmos A/S (Denmark) Sanofi US (USA) Vifor Pharma Ltd. (Switzerland) Vifor Fresenius Medical Care Renal Pharma (Switzerland) 7. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 21 (including Divisions/Subsidiaries 22) The United States ((5) Japan (2) Europe (7) - France (1) - Germany (1) - The United Kingdom (1) - Rest of Europe (4) Asia-Pacific (Excluding Japan) (8)
For more information about this report visit https://www.researchandmarkets.com/research/b...us_iv?w=12
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Infusions and Injectables , Hematological Drugs
